With Bristol Myers Squibb (BMS) now rolling out the SC version of rival nivolumab (Opdivo Qvantig), the shift from 30-minute intravenous (IV) infusion to 5-minute SC injection could be one of the most ...
Subcutaneous ocrelizumab (SC OCR) maintains a safety profile similar to intravenous administration in multiple sclerosis patients. A 920 mg SC OCR dose was identified as optimal, with mild to moderate ...
Healthcare professionals most commonly use body parts with little hair as intradermal injection sites. Examples include the inner surface of the forearm and the upper back, under the scapula.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback